Aprepitant
For Laboratory Research Only. Not for Clinical or Personal Use.
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No


Aprepitant
Description :
Aprepitant (MK-0869) is a selective and high-affinity neurokinin 1 receptor antagonist with a Kd of 86 pM.Product Name Alternative :
MK-0869; MK-869; L-754030UNSPSC :
12352005Hazard Statement :
H302, H315, H319, H335Target :
Antibiotic; Bacterial; HIV; Neurokinin ReceptorType :
Reference compoundRelated Pathways :
Anti-infection; GPCR/G Protein; Neuronal SignalingApplications :
Cancer-programmed cell deathField of Research :
Neurological Disease; Endocrinology; CancerAssay Protocol :
https://www.medchemexpress.com/Aprepitant.htmlPurity :
99.82Solubility :
DMSO : 50 mg/mL (ultrasonic)Smiles :
O=C1NC(CN2[C@H]([C@@H](O[C@@H](C3=CC(C(F)(F)F)=CC(C(F)(F)F)=C3)C)OCC2)C4=CC=C(F)C=C4)=NN1Molecular Formula :
C23H21F7N4O3Molecular Weight :
534.43Precautions :
H302, H315, H319, H335References & Citations :
[1]Martinez AN, et al. Aprepitant limits in vivo neuroinflammatory responses in a rhesus model of Lyme neuroborreliosis. J Neuroinflammation. 2017 Feb 15;14 (1) :37.|[2]Bayati S, et al. Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells. Eur J Pharmacol. 2016 Nov 15;791:274-283.|[3]Mannangatti P, et al. Differential effects of aprepitant, a clinically used neurokinin-1 receptor antagonist on the expression of conditioned psychostimulant versus opioid reward. Psychopharmacology (Berl) . 2017 Feb;234 (4) :695-705.|[4]Barrett JS, et al. Pharmacologic rationale for the NK1R antagonist, aprepitant as adjunctive therapy in HIV. J Transl Med. 2016 May 26;14 (1) :148.Shipping Conditions :
Room TemperatureStorage Conditions :
4°C (Powder, protect from light)Scientific Category :
Reference compound1Clinical Information :
LaunchedCAS Number :
[170729-80-3]

